The difficulties in accessing laboratory testing and securing prompt results present continuing challenges in the fight to control COVID-19. With scarce availability, there have been some attempts to limit tests to, or prioritize tests for, those with symptoms or who serve in essential roles, such as healthcare workers. However, there clearly remains a need, and a demand, for testing for asymptomatic individuals.
Currently, FDA has not authorized a COVID-19 test for asymptomatic surveillance despite many employers, including professional athletic teams, requiring testing of asymptomatic individuals. Even some states require such testing. For example, as part of its Keep Maine Healthy initiative, Maine is requiring visitors from other states to: 1) get a recent negative COVID-19 test in advance of entering; 2) maintain compliance with a 14-day quarantine upon arrival in Maine; 3) or enjoy an exemption if the visitor is from nearby states with a similar or better COVID-19 experience than Maine. Visitors must sign a Certificate of Compliance attesting to compliance with the aforementioned requirements.
To date, FDA has only authorized molecular diagnostic tests for symptomatic, pre-symptomatic, or asymptomatic individuals suspected of having COVID-19 by their healthcare provider. Testing compliant with FDA authorization is only possible on the theory that healthcare providers have the discretion to test asymptomatic individuals when, in the professional judgement of the healthcare provider, a COVID-19 test is warranted for a particular individual, although compliance with that standard may be suspect.
In this context, FDA released a statement, Coronavirus (COVID-19) Update: Facilitating Diagnostic Test Availability for Asymptomatic Testing and Sample Pooling, which outlines the steps for a test to be authorized for broad screening of asymptomatic individuals. The statement provides information for test developers on the FDA’s expectations for how these tests can be validated for screening of asymptomatic individuals.
In its recent statement, FDA has acknowledged that organizations may want to conduct screening of asymptomatic individuals as part of a broader strategy to help ensure the safety of their employees, patients, students, and others. FDA provided updated templates for test developers to use in connection with developing and validating test for broad screening of asymptomatic individuals, including FDA’s expectations for developers of molecular diagnostic tests who intend for their assays to be used for pooling patient samples or for screening asymptomatic individuals not suspected of having COVID-19. FDA also made available additional FAQs with information regarding tests for screening asymptomatic individuals.
FDA’s latest statement provides a quicker pathway for approving more tests, which will be a necessity as the U.S. continues reopening, and employers, for example, devise plans for how to bring people back to the workplace safely.
For more information, please contact your Foley relationship partner or the Foley author listed below. Companies in all sectors of the economy continue to be impacted by COVID-19. Foley’s here to help our clients effectively address the short- and long-term impacts on their business interests, operations, and objectives. Foley provides insights and strategies across multiple industries and disciplines to provide timely perspective on the wide range of legal and business challenges that companies face conducting business while dealing with the impact of the coronavirus. Click here to stay up to date and ahead of the curve with our key publications addressing today’s challenges and tomorrow’s opportunities. To receive this content directly in your inbox, click here and submit the form.